论文部分内容阅读
对HbA1c>9%的新诊断的T2DM患者给予格列美脲联合二甲双胍治疗12周,观察BMI、FPG、2hPG、HbA1c、FINS、2hINS、HOMA-IR变化及低血糖发生率。结果治疗后FPG、2 h PG、HbA1c均显著下降(P<0.01);HOMA-IR下降、HOMA-β升高(P均<0.01);TG、TC、LDL均显著下降(P<0.01)。低血糖发生少。结论:HbA1c>9%的新诊断的T2DM患者给予格列美脲联合二甲双胍可提供良好的血糖控制,患者依从性好,是安全有效而简便的治疗方案。
The newly diagnosed T2DM patients with HbA1c> 9% were treated with glimepiride and metformin for 12 weeks. The changes of BMI, FPG, 2hPG, HbA1c, FINS, 2hINS, HOMA-IR and the incidence of hypoglycemia were observed. Results The levels of FPG, 2 h PG and HbA1c were significantly decreased (P <0.01), HOMA-IR was decreased, HOMA-β was increased (all P <0.01), TG, TC and LDL were significantly decreased. Hypoglycemia occurs less. CONCLUSIONS: Glimepiride combined with metformin provides a good glycemic control in newly diagnosed T2DM patients with> 9% HbA1c, and is a safe, effective and facile regimen for patients with good compliance.